

Medical Drug Clinical Criteria

Subject: Nexobrid (anacaulase-bcddb)

Document #: CC-0260

Status: Reviewed

Publish Date: 10/23/2024 10/24/2025

Last Review Date: 09/09/2024 09/08/2025

Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

Overview

This document addresses the use of Nexobrid (anacaulase-bcddb). Nexobrid contains proteolytic enzymes and is FDA approved for eschar removal in people with deep partial thickness and/or full thickness thermal burns. Nexobrid is administered by a healthcare professional in up to two applications 4 hours apart. Up to 20% BSA (40 grams of Nexobrid) can be treated across two treatment sessions.

Escharotomies are procedures done in partial or full thickness thermal burns to relieve eschar tightness, assess extent of wounds and need for grafts. Eschar removal can be done surgically, with enzymatic debridement or allowing the natural process of debridement to occur. Nexobrid is an enzymatic form of eschar removal.

Clinical Criteria

Nexobrid (anacaulase-bcddb)

Requests for Nexobrid (anacaulase-bcddb) may be approved if the following criteria are met:

- I. Individual is using for eschar removal of deep partial thickness and/or full thickness thermal burns

Requests for Nexobrid (anacaulase-bcddb) may not be approved for the following:

- I. Individual with chemical or electrical burns; **OR**
- II. Individual is treating burns to the face, perineum, or genitalia; **OR**
- III. Individual is treating burns on the feet and is also diagnosed with diabetes mellitus or an occlusive vascular disease; **OR**
- IV. Individual is treating circumferential burns; **OR**
- V. Individual has significant cardiopulmonary disease, including inhalation injury.

Quantity Limits

Quantity Limits

Drug	Limit
Nexobrid (anacaulase-bcddb) for topical gel	440 grams per 2 days

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

ICD-10-PCS

XW00X27

Introduction of Bromelain-enriched Proteolytic Enzyme-Anacaulase-bcddb into Skin, External Approach, New Technology Group 7

XW01X27 Introduction of Bromelain-enriched Proteolytic Enzyme-Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

HCPCS

J7353 Anacaulase-bcdb, 8.8% gel, 1 gram [Nexobrid]

ICD-10-CM

T30.0-T31.99	Burn and corrosion, body region unspecified, Burns classified according to extent of body surface involved
T21.20XA-T21.39XA	Burn of second <u>or third</u> degree of trunk, <u>Burn of third degree of trunk</u>
T22.20XA-T22.399A	Burn of second <u>or third</u> degree of shoulder and upper limb, except wrist and hand
T23.201A- T23.399A	Burn of second degree of wrist and hand, Burn of third degree of wrist and hand
T24.201A- T24.399A	Burn of second degree of lower limb, except ankle and foot, Burn of third degree of lower limb, except ankle and foot
T25.211A-T25.399A	Burn of second degree of ankle and foot, Burn of third degree of ankle and foot

Document History

Reviewed: 09/08/2025

Document History:

- 09/08/2025 – Annual Review: No Changes. Coding Reviewed: Updated description for ICD-10-PCS XW00X27, XW01X27 and ICD-10-CM T22.20XA-T22.399A.
- 09/09/2024 – Annual Review: No Change. Coding Reviewed: No changes. Coding Reviewed: Revised ICD-10-CM to T30.0-T31.99, T21.20XA-T21.39XA, T22.20XA-T22.399A, T23.201A- T23.399A, T24.201A- T24.399A, T25.211A-T25.399A and changed diagnoses descriptions.
- 04/01/2024 – Select Review: Add new clinical document for Nexobrid (anacaulase-bcdb). Coding Reviewed: Added ICD-10-PCS XW00X27- XW01X27. Added ICD-10-CM T300-T3199, T2120XA-T2139XA, T2220XA-T22399A, T23201A- T23399A, T24201A- T24399A, T25211A-T25399A.

References

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. A Study to Evaluate the Efficacy and Safety of Nexobrid in Subjects With Thermal Burns. Clinic, alTrials.gov identifier: NCT02148705. Updated February 19, 2019. <https://clinicaltrials.gov/ct2/show/study/NCT02148705>
5. Shoham Y, Rosenberg L, Hickerson W, et al. Early enzymatic burn debridement - results of the DETECT multicenter Randomized Controlled Trial [published online ahead of print, 2023 Sep 16]. J Burn Care Res. 2023;irad142. doi:10.1093/jbcr/irad142

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association